Sodium thiopental is a fast-acting barbiturate anesthetic, first developed in 1936, that for most of the twentieth century was the standard drug used to put surgical patients to sleep. It is not formally banned in the United States, but it has become almost impossible to obtain here. The last domestic manufacturer stopped making it in 2011 after the drug became the first injection in state execution protocols, and the European Union blocked exports of it for the same reason. Propofol and other modern anesthetics now fill its clinical role, while its name survives mostly in debates over capital punishment and the old legend of “truth serum.”
What Sodium Thiopental Is and How It Works
Sodium thiopental belongs to the barbiturate family, a class of sedatives derived from barbituric acid. It acts on GABA-A receptors in the brain, prolonging the time that chloride ion channels stay open and quieting electrical activity across the central nervous system. At higher concentrations it can activate those receptors directly, without any GABA present at all.1PubMed Central. Stereoselective Interaction of Thiopentone Enantiomers The result is deep sedation, with a narrow margin between the dose that produces unconsciousness and the dose that dangerously suppresses breathing and circulation.
What made the drug so useful in operating rooms was its speed. Its chemical structure is highly lipid-soluble, so after an intravenous injection it crosses the blood-brain barrier almost instantly. A patient typically loses consciousness within about thirty seconds. The effect also wears off quickly, but not because the body breaks the drug down fast. It redistributes out of brain tissue into muscle and fat, dropping the brain concentration while the liver handles the slower work of actual metabolism.
Medical Uses and Why Hospitals Switched to Propofol
For decades, sodium thiopental was the default induction agent in general anesthesia. Clinicians would inject it to put a patient under, then switch to inhaled gases or longer-acting sedatives to keep them there. It also had specialized roles in neurocritical care: it is a recognized treatment for status epilepticus, the life-threatening condition of continuous seizures that do not respond to first-line drugs, and it has been used to reduce dangerous intracranial pressure after severe head injuries by lowering the brain’s metabolic demand.
Starting in the 1990s, propofol gradually replaced it as the standard induction agent. Propofol offered a smoother recovery and fewer side effects for routine surgery. Sodium thiopental held on in certain neurological, cardiovascular, and obstetric situations where its profile had advantages, and the World Health Organization still lists it as an alternative to propofol on its essential medicines list. In the United States, though, the clinical question is now largely academic, because the drug is no longer being made or imported.
The drug is not forgiving to administer. It causes respiratory depression and drops in blood pressure, and it is flatly contraindicated in people with porphyria, where barbiturates can trigger acute, potentially fatal attacks. It is also contraindicated in patients with airway obstruction, severe asthma, and certain neuromuscular conditions.2Health Products Regulatory Authority (HPRA). Thiopental Sodium 500mg/1g Powder for Solution for Injection – Summary of Product Characteristics
How It Became the First Drug in Lethal Injection
Sodium thiopental became central to American capital punishment through a three-drug sequence Oklahoma developed in 1977. States adopted the same protocol: sodium thiopental first, to render the person deeply unconscious; then pancuronium bromide, to paralyze the muscles; and finally potassium chloride, to stop the heart. The barbiturate’s role was critical, because the paralytic would cause suffocation and the potassium chloride would burn severely in a conscious person.3PubMed Central. Lethal Injection for Execution – Chemical Asphyxiation
The Supreme Court upheld this protocol in Baze v. Rees (2008). The Court held that Kentucky’s three-drug sequence, beginning with sodium thiopental, did not violate the Eighth Amendment’s ban on cruel and unusual punishment. The plurality found that properly administered, the protocol presented a low risk of severe pain, and that the petitioners had not shown a feasible, readily available alternative that would significantly reduce that risk.4Legal Information Institute. Baze v Rees
Why Sodium Thiopental Is No Longer Available
The protocol survived the courts and then collapsed in the supply chain. In January 2011, Hospira Inc., the sole remaining U.S. manufacturer of sodium thiopental, announced it would stop producing the drug. The company had planned to move production to an Italian facility, but the Italian government required a guarantee that the drug would not be used in executions. Hospira concluded it could not prevent correctional departments from obtaining it, and could not accept the liability. Production ended entirely.
European regulators then cut off the backstop. The EU adopted Commission Implementing Regulation No. 1352/2011, restricting exports of goods that could be used for capital punishment or torture. European manufacturers had been the primary global source, so the regulation effectively ended the international supply U.S. corrections departments had relied on.5EUR-Lex. Commission Implementing Regulation (EU) No 1352/2011
Some states tried to import the drug through unofficial channels. That triggered Cook v. FDA (2013), in which the D.C. Circuit ruled that the FDA had violated federal law by letting foreign-manufactured sodium thiopental into the country without proper inspection. The drug had been prepared by a firm not registered with the FDA, and the agency’s policy of admitting it anyway was “not in accordance with law.”6Justia Law. Cook, et al v FDA, et al, No 12-5176 (DC Cir 2013)
With sodium thiopental unavailable, states moved on. Ohio was the first to adopt a single-drug protocol using pentobarbital in March 2011. Texas, Georgia, Missouri, Idaho, Indiana, South Dakota, and the federal government followed with the same switch.7Death Penalty Information Center. State-by-State Execution Protocols As pentobarbital supplies also dried up, some states turned to midazolam, a benzodiazepine that is pharmacologically weaker than a barbiturate and does not produce the same depth of unconsciousness. In Glossip v. Gross (2015), the Supreme Court allowed Oklahoma to use midazolam, holding that the inmates had not shown a substantial risk of severe pain compared to a “known and available alternative,” and noting that sodium thiopental and pentobarbital were themselves unavailable to the state.8Justia US Supreme Court. Glossip v Gross, 576 US 863 (2015)
The “Truth Serum” Reputation
Outside the operating room and the execution chamber, sodium thiopental is best known as a supposed truth serum. In psychiatric practice the technique was called narcoanalysis: a clinician would give a low dose to lower a patient’s inhibitions, then guide them through discussions of repressed memories. Law enforcement and intelligence agencies hoped the same principle could compel truthful answers from unwilling subjects.
For criminal cases, the Supreme Court closed that door in Townsend v. Sain (1963). The Court held that any confession produced while a person’s will was overborne by a drug with “truth serum” properties is involuntary and constitutionally inadmissible. It does not matter whether the officers or clinicians involved understood the drug’s properties. If the drug in fact produced a statement that was not the product of a free intellect, the statement cannot be used as evidence.6Justia Law. Cook, et al v FDA, et al, No 12-5176 (DC Cir 2013) Federal courts have treated drug-induced statements with the same skepticism as physically coerced ones ever since.
Legal Classification and Penalties Today
Sodium thiopental is not an illegal drug. As a barbiturate derived from barbituric acid, it sits in Schedule III of the Controlled Substances Act, the category used for drugs with accepted medical uses and a moderate potential for abuse. The federal scheduling regulations place all barbituric acid derivatives in Schedule III unless they are specifically listed elsewhere.9eCFR. 21 CFR Part 1308 – Schedules of Controlled Substances – Section 1308.13 Schedule III Any facility that possesses it must meet DEA storage, inventory, and record-keeping standards.
Penalties for illegally distributing a Schedule III substance are serious. A first offense carries up to 10 years in federal prison and a fine of up to $500,000 for an individual. If someone dies or suffers serious bodily injury as a result, the ceiling rises to 15 years. A second offense after a prior felony drug conviction doubles the exposure, up to 20 years in prison, or 30 years if death or serious injury results, with individual fines reaching $1 million. At least two years of supervised release follow a first-offense prison sentence, and at least four years follow a second.10Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A
The practical result is a drug that remains legal on paper but has effectively vanished from American medicine and American prisons. No domestic manufacturer makes it, European exporters cannot ship it, the FDA cannot wave in uninspected foreign batches, and hospitals that once relied on it have moved on to propofol. Capital punishment protocols have been rewritten around substitutes whose adequacy is still being argued in court.